RE:RE:RE:RE:RE:RE:ONCY's pelareorep activates interferon (IFN) signallingCancer immunotherapy is based on using the immune system components to fight tumors, without destroying normal cells.
Many tumors can resist immunotherapy due to the absence or insufficient infiltration of tumors with CD8+ T cells and hence, are called “cold” or non-inflammatory tumors. Cold tumors are characterized by a lack of infiltrating CD8+ T cells, the presence of anti-inflammatory myeloid cells, tumor-associated M2 macrophages, and regulatory T cells.
ONCY's pelareorep (reovirus) capabiltiy of remodeling an immunosuppressive / hypoxic tumor microenvironment (TME) results in the ability upregulating of turning "cold" tumors into "hot" tumors through innate and adaptive immune responses to treat a variety of cancers, and overcoming the issue of T-Cell exhaustion through clonal proliferation of T-cell and the prevention of MHC-1 loss through the expanded expression of MHC-1 ligand (Murphy et al., 2019), leading to the increase of CD8+ T-cells, along with dendritic and NK immune cells involved in the "cross priming" in the TME.
Cross priming is a process which dendritic cells activate CD8+ T cells by cross presenting exogenous antigens, and plays a critical role in generating anti-tumor CD8+ T-cell immunity, which is an accomplishment that ONCY's oncolytic virus pelareorep has demonstrated in ONCY's Aware-1, Bracelet-1 and Goblet-1 Phase 2 clinical trials. .